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ﺕﺎﺒﻛﺮﻣﺔﻌﺒﺳﺮﻴﻀﺤﺘﻟﺕﺍﻮﻄﺧ٥ﻦﻣﺔﻧﻮﻜﻣﺔﻘﻳﺮﻃﻢﻴﻤﺼﺗﻢﺗ:ﺚﺤﺒﻟﺍﻑﺪﻫﺃ
ﻒﺸﻜﻟﺍﻭﺔﻴﺋﺍﺪﺘﺑﺍﺕﺎﺒﻛﺮﻤﻛﺖﻳﺮﺒﻜﻟﺍﻰﻠﻋﻱﻮﺘﺤﺗﻝﻭﺯﺎﻳﺍﺮﺘﻟﺍ-١,٢,٤ﺕﺎﻘﺘﺸﻣﻦﻣ
.ﻲﺋﺍﻭﺪﻟﺍﻢﻬﻃﺎﺸﻧﻦﻋ
ﺕﺎﻧﺎﻴﺒﻟﺍﻭﺮﺻﺎﻨﻌﻟﺍﻞﻴﻠﺤﺗﻖﻳﺮﻃﻦﻋﺕﺎﺒﻛﺮﻤﻟﺍﻩﺬﻫﻒﻴﺻﻮﺗﻢﺗ:ﺚﺤﺒﻟﺍﻕﺮﻃ
ﻩﺎﺠﺗﺕﺎﺑﻭﺮﻜﻴﻤﻠﻟﺩﺎﻀﻤﻟﺍﺎﻬﻃﺎﺸﻨﻟﺕﺎﺒﻛﺮﻤﻟﺍﻩﺬﻫﻊﻴﻤﺟﻢﻴﻴﻘﺗﻢﺗﻭ.ﺔﻴﻋﺎﻤﺠﻟﺍﺔﻴﻔﻴﻄﻟﺍ
ﺙﺎﺤﺑﻷﺍﻲﻓﺓﺭﻮﻛﺬﻤﻟﺍﻕﺮﻄﻟﺍﺐﺴﺣﺕﺎﻳﺮﻄﻔﻟﺍﻭﺎﻳﺮﻴﺘﻜﺒﻟﺍﻦﻣﺓﺭﺎﺘﺨﻣﺕﺎﻨﻴﻋ
.ﻮﻜﻴﻠﻴﺳﺕﺎﺳﺍﺭﺩﻝﻼﺧﻦﻣﺔﻴﺋﺍﻭﺪﻟﺍﻪﺒﺷﺺﺋﺎﺼﺨﻟﺍﻢﻴﻴﻘﺗﻢﺗﻭ.ﺔﻘﺑﺎﺴﻟﺍ
.ﺕﺎﺑﻭﺮﻜﻴﻤﻟﺍﺕﺍﺩﺎﻀﻤﻟﺎﻄﺳﻮﺘﻣﺎﻃﺎﺸﻧﺕﺮﻬﻇﺃﺝ٨،ﺏ٨،ﺃ٨ﺕﺎﺒﻛﺮﻤﻟﺍ:ﺞﺋﺎﺘﻨﻟﺍ
،ﻮﻣﻭﺮﺑ،ﻭﺭﻮﻠﻛ،ﻭﺮﺘﻴﻧﺕﺎﻘﺘﺸﻣﺔﻴﻤﺴﻤﻟﺍﻭﺯ٨،ﻭ٨،ـﻫ٨،ﺩ٨ﺕﺎﺒﻛﺮﻣﺎﻣﺃ
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ﻭﺭﻮﻠﻜﻟﺍﻊﻣـﻫ٨ﺐﻛﺮﻣﻥﺃﻮﻜﻴﻠﻴﺴﻟﺍﺕﺎﺳﺍﺭﺩﺖﺤﺿﻭﺃ.ﻯﺮﺧﻷﺍﺕﺎﺒﻛﺮﻤﻟﺎﺑ
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p://dx.doi.org/10.1016/j.jtumed.2014.06.002Abstract
Objectives: To design a five step procedure for the syn-
thesis of seven novel sulphur containing 1,2,4-triazole
derivatives namely 4-[(3-(4-Chloro-phenoxymethyl)-5-(4-
substituted-benzylsulfonyl)-1,2,4-triazol-4-yl)methyl]-
morpholine from 4-Chloro-phenol and Ethyl-
bromoacetate as starting compounds and to screen for
their pharmacological activity.
Methods: The compounds were characterised by
elemental analysis, IR, 1H NMR and mass spectral data.
All compounds were evaluated for antimicrobial activity
against selected bacteria and fungi by the methods re-
ported in the literature. The drug-like characteristics were
assessed by in silico studies.
Results: The compounds 8a, b and c showed moderate
antimicrobial activity. Compounds 8d, e, f and g namely
nitro, chloro, bromo and fluoro derivatives respectively,
showed better antimicrobial activity than the other
compounds. In silico studies indicated that the compound
8e with chloro substituent possesses excellent drug-like
characteristics among the compounds under study.
Conclusion: All the title compounds showed good anti-
bacterial and antifungal activities. Virtual screening
studies reveal that the compounds under study possess
excellent drug-like characteristics.
Keywords: Synthesis; 1,2,4-triazole derivatives; Spectral
analysis; Antimicrobial activity; Drug-like characteristics
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In the last few years, 1,2,4-triazoles and their fused het-
erocyclic derivatives have received considerable attention
owing to their medicinal significance. Several drugs con-
taining 1,2,4-triazole group i.e. Etizolam,1 Alprazolam,2
Furacylin3 etc are well known. Particularly, diverse
biological activities, such as antibacterial,4 antifungal,5
anti-inflammatory,6 antituberculosis,7 anticancer,8
antioxidant9 and InhA inhibitory activity10 etc. have been
associated with 1,2,4-triazole derivatives. Keeping in view
the above mentioned facts and the medicinal importance of
sulphur containing 1,2,4-triazole ring systems,11e14 the
authors have made an attempt to synthesize, characterize
and evaluate the biological activity of some sulphur
containing 1,2,4-triazoles. A number of pharmacologically
active compounds have been reported15e17 from these
laboratories.Materials and Methods
All Chemicals and reagents were procured from Ran-
baxy Laboratories Ltd, Chemical Division, India. The
standard bacterial and fungal strains were procured from
National Centre for Cell Sciences, Pune, India. Nutrient
broth, nutrient agar and 5 mm diameter antibiotic assay
discs were obtained from Hi-Media Laboratories Limited,
India. Melting points were determined by Scientific
melting point apparatus, India and uncorrected. Synthe-
sized compounds were recrystallized using suitable solvent.
Digital electronics balance (Shankar Scientific Supplies,
India), horizontal laminar air flow bench (Yorco Sales Pvt.
Ltd, New Delhi, India), incubator (Yorco Sales Pvt. Ltd,
New Delhi, India), zone reader (Cintex Industrial
Corporation, India), hot air oven, autoclave and UV-
Visible spectrophotometer (Shimadzu Corporation,
Japan) were used for respective investigations. Elemental
analysis was carried out on CHNS/O Elemental Analyser
manufactured by PerkinElmer. The amount of halogens
present in the compound was determined by the procedure
reported in the literature.18 Infrared spectra of the
compounds were recorded in KBr discs on Perkin-Elmer
FT-IR spectrometer (ymax in cm
1). 1H NMR spectra
were recorded on a JOEL (300 MHz) spectrometer using
TMS as an internal standard (chemical shifts in d). The
mass spectra were recorded on a mass spectrometer JOEL
sx-102.
Experimental section
Synthesis of ethyl-2-(4-chlorophenoxy)acetate (2)
4-Chloro-phenol (5 g, 29 mmol, 1.0 eq.) was added to a
stirred suspension of Sodium hydride (1.12 g, 46.8 mmol, 1.2
eq) in DMF (25 mL) and the reaction mixture was stirred for
30 min. Ethylbromoacetate (9.8 g, 58 mmol, 1.5 eq) wasadded drop wise and was stirred for 3 h. The reaction mixture
was poured in cold water, extracted with Ethyl acetate,
organic layer was washed with water, brine solution, dried
over anhydrous Sodium sulphate and the solvent was
removed under reduced pressure to get crude compound.
The crude solid was purified by silica gel (100e200 mesh)
column chromatography, eluted with 2% Ethylacetate/Pe-
troleum ether to get pure Ethyl-2-(4-chlorophenoxy)acetate
(Yield:76%).Synthesis of 2-(4-Chlorophenoxy)acetohydrazide (3)
A mixture of Hydrazine hydrate (0.980 g, 19.6 mmol,
4 eq.), Ethyl-2-(4-chlorophenoxy)acetate (2) (2.1 g,
9.8 mmol,1 eq.) in Ethanol (20 mL) was refluxed for 12 h.
The reaction mixture was cooled to room temperature,
filtered, so obtained solid was washed with Ethanol and dried
under vacuum to get pure 2-(4-Chlorophenoxy)acetohy-
drazide (Yield:71%).Synthesis of 1-(2-(4-Chlorophenoxy)acetyl)
thiosemicarbazide (4)
Potassium thio cyanate (10.7 g, 110 mmol, 3.5 eq.) was
added to a stirred solution of 2-(4-Chlorophenoxy)acetohy-
drazide (3) (6.2 g, 31 mmol,1 eq) in H2O (31 mL) and HCl
(7.75 mL) and the reaction mixture was heated to 90 C for
4 h. The reaction mixture was cooled to room temperature,
diluted with water and filtered. The solid so obtained was
dried under vacuum to get crude 1-(2-(4-Chlorophenoxy)
acetyl) thiosemicarbazide (Yield:79%).Synthesis of 5-(4-Chlorophenoxymethyl)-2,4-dihydro-1,2,4-
triazole-3-thione (5)
1-(2-(4-Chlorophenoxy)acetyl) thiosemicarbazide (4)
(0.500 g, 1.92 mmol) was dissolved in saturated K2CO3
(70.0 mL) solution and stirred at room temperature for 2
days. The reaction mixture was filtered and the filtrate was
acidified with 2N HCl. The reaction mixture was filtered and
solid so obtained was dried under vacuum to get pure 5-(4-
Chlorophenoxymethyl)-2,4-dihydro-1,2,4-triazole-3-thione
(Yield:69%).Synthesis of 3-Benzylsulfanyl-5-(4-chloro-phenoxymethyl)-
4H-1,2,4-triazole (6a)
To a stirred solution of Potassium hydroxide in Ethanol
(0.300 g in 15 mL), 5-(4-Chlorophenoxymethyl)-2,4-dihydro-
1,2,4-triazole-3-thione (5) (0.483 g, 2 mmol) and Benzyl
chloride (12 mL) were added. The reaction mixture was
heated to reflux temperature for 4 h. The reaction mixture
was cooled to room temperature, diluted with water and
extracted with Ethylacetate. The organic layer was washed
with water, brine solution, dried over anhydrous Sodium
sulphate and the solvent was removed under reduced pres-
sure to obtain 3-Benzylsulfanyl-5-(4-chloro-phenox-
ymethyl)-4H-1,2,4-triazole (6a). The product was isolated by
recrystallization from a mixture of Ethylacetate-petroleum
ether (1:1) (Yield:70%).
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phenoxymethyl)-1,2,4-triazole-4-ylmethyl]-morpholine
(7a)
A mixture of 3-Benzylsulfanyl-5-(4-chloro-phenox-
ymethyl)-4H-1,2,4-triazole (6a), (0.650 g, 1.6 mmol), Mor-
pholine (6 mL) and water (15 mL) was stirred to obtain a clear
solution. To this solution Formaldehyde (10 mL) and
Dimethyl formamide (6 mL) were added, stirred for 2 h in ice-
bath and left overnight at room temperature. White solid was
isolated and recrystallized from Ethanol to give 4-[3-
Benzylsulfanyl-5-(4-chloro-phenoxymethyl)-1,2,4-triazole-4-
ylmethyl]-morpholine (7a) (Yield:71%). The procedure lead-
ing to the synthesis of 7a was extended to the synthesis of 7b-g.
Synthesis of 4-[(3-(4-Chloro-phenoxymethyl)-5-
benzylsulfonyl)-1,2,4-triazol-4-yl)methyl]-morpholine 8a
To a solution of 4-[3-Benzylsulfanyl-5-(4-chloro-
phenoxymethyl)-1,2,4-triazole-4-ylmethyl]-morpholine (7a)
(0.700 g, 1.5 mmol) in Glacial acetic acid (5 mL), 30%
Hydrogen peroxide (6.5 mL) was added and refluxed for
about 2 h. The reaction mixture was cooled, filtered and solid
obtained was recrystallized from Ethanol solution. The
procedure leading to formation of 8a was extended for the
synthesis of 8be8g. The structure of 8ae8g was confirmed by
elemental analysis, IR, 1H NMR and mass spectral data. The
reaction scheme is shown in the Scheme 1.
Antimicrobial activity
Disc diffusion method
A suspension of Staphylococcus aureus was added to
sterile nutrient agar at 45 C. The mixture was transferred to(1)
Cl
OH BrCH2COOC2H5
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Scheme 1: Synthesis of 4-[(3-(4-Chloro-phenoxymethyl)-5-(4-subststerile petridishes to give a depth of 3 to 4 mm and allowed to
solidify. Sterile discs of 5 mm diameter (made from What-
mann Filter paper) were immersed in solutions of synthe-
sized compounds (50 mg/ml) and untreated control sample
was also prepared for comparison.
A period of pre incubation diffusion (1 h at room tem-
perature) was ensured to minimize the effects of variations in
time. The plates were incubated at 37 C for 24 h and
observed for antibacterial activity. The diameter of zone of
inhibition was measured for each plate in which the zone of
inhibition was observed. The average zone of inhibition was
calculated and compared with that of the standard. Similar
procedure was adopted for studying the antimicrobial ac-
tivity against the other organisms.Broth dilution method
Minimum Inhibitor Concentration was found out by
broth dilution method. Standardized Inoculum (matched to
McFarland BaSO4 standard) of suspension of organisms
were prepared. A series of glass tubes containing different
concentrations of test compounds dissolved in Dime-
thylsuphoxide and spiller in nutrient broth were incubated
with one drop of inoculum and mixed gently by shaking the
rack. Two growth control tubes were also prepared without
the addition of test compound and its optical density was
determined. The tubes were incubated for 24 hours at 37 C
in air. The turbidity produced in each tube was recorded by
UV-Visible spectrophotometer. The turbidity produced by
the broth (without inoculum) was considered as 100%
transparency. Minimum inhibitory concentration (MIC) was
noted as the concentration of the test substance, which
completely inhibits the growth of the microorganism i.e.
100% transparency.N2H4
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Cefaclor and the antifungal activity was compared with that
of Ketoconazole.
Results
The novel compounds synthesised were characterised by
elemental analysis, IR and, 1H NMR and mass spectral data.
Elemental analysis details of 4-[(3-(4-Chloro-phenox-
ymethyl)-5-(4-substituted-benzylsulfonyl)-1,2,4-triazol-4-yl)
methyl]-morpholine 8 are given in the Table 1.
The characterisation details are given below.
IR spectral data of Ethyl-2-(4-Chlorophenoxy)acetate (2)
Aromatic Ar-H (3058 cm1), aliphatic-CH2-(2923 cm1)
and >C]O of eCOOEt (1656 cm1).
1H NMR spectral data of Ethyl-2-(4-Chlorophenoxy)ac-
etate (2)
d.7.21 (d, 2H, Ar-H); 7.1 (d, 2H, Ar-H); 4.9 (s, 2H,
-O-CH2-); 4.0 (q, 2H, -CH2 of ethyl group); 1.21 (t, 3H, CH3
of ethyl group).
IR spectral data of 2-(4-Chlorophenoxy)acetohydrazide (3)
NH2 (3425 cm
1); NH (3125 cm1); Aromatic Ar-H
(3060 cm1); aliphatic -CH2-, (2928 cm1) and >C]O of
eCO-NH- (1645 cm1).
1H NMR spectral data of 2-(4-Chlorophenoxy)acetohy-
drazide (3)
d 2.80 (broad s, 2H, -NH2); 5.20 (s, 2H, -O-CH2-); 7.00 (d,
2H, Ar-H); 7.20 (d, 2H, Ar-H); 9.1 (broad s, 1H, -CO-NH-).
IR spectral data of 1-(2-(4-Chlorophenoxy)acetyl)thio-
semicarbazide (4)
NH2 (3420 cm
1); NH (3130 cm1); Aromatic Ar-H
(3064 cm1); aliphatic -CH2- (2930 cm1); >C]O of eCO-
NH- (1648 cm1); N-N (1550 cm1) and C]S (1134 cm1).
1H NMR spectral data of 1-(2-(4-Chlorophenoxy)acetyl)
thiosemicarbazide (4)
d 2.70 (broad s, 2H, -NH2); 5.10 (s, 2H, -O-CH2-); 7.10 (d,
2H, Ar-H); 7.20 (d, 2H, Ar-H); 9.15 (broad s, 1H, -CO-NH-).
IR spectral data of 5-(4-Chlorophenoxymethyl)-2,4-
dihydro-1,2,4-triazole-3-thione (5)
NH (3136 cm1); Aromatic Ar-H (3066 cm1); aliphatic
-CH2- (2932 cm
1); >C]N, (1597 cm1); N-N (1615 cm1)
and C]S (1143 cm1).
1H NMR spectral data of5-(4-Chlorophenoxymethyl)-2,4-
dihydro-1,2,4-triazole-3-thione (5)
d 5.10 (s, 2H, -O-CH2-); 6.80 (d, 1H, Ar-H); 7.10 (s, 1H,
Ar-H); 7.20 (s, 2H, Ar-H); 7.40 (d, 2H, Ar-H); 8.15 (broad s,Table 1: Characterization data of 4-[(3-(4-Chloro-phenoxymethyl
pholine 8.
Compd. Molecular formula Yield (%) m. p(C) Analysis (%) fou
C H
8a C21H23ClN4O4S 51,156e159 54.32 (54.48) 4.8
8b C22H25ClN4O4S 53,167e170 55.04 (55.40) 5.3
8c C22H25ClN4O5S 47,147e150 53.84 (53.60) 5.2
8d C21H23ClN5O6S 48,164e168 48.91 (49.66) 4.2
8e C21H23Cl2N4O4S 50,173e175 51.05 (50.71) 4.2
8f C21H22BrClN4O4S 52,169e171 46.41 (46.55) 4.5
8g C21H22FClN4O4S 50,175e179 52.53 (52.44) 4.41H, -C]S-NH-); 14.70 (broad signal due to thio-thione
tautomeric form).
IR spectral data of 3-Benzylsulfanyl-5-(4-chloro-phenox-
ymethyl)-4H-1,2,4-triazole (6a)
NH (3140 cm1); Aromatic Ar-H (3068 cm1); aliphatic
-CH2- (2934 cm
1); >C]N (1599 cm1) and N-N
(1640 cm1).
1H NMR spectral data of 3-Benzylsulfanyl-5-(4-chloro-
phenoxymethyl)-4H-1,2,4-triazole (6a)
d 4.90 (s, 2H, -S-CH2-); 5.30 (s, 2H, -O-CH2-); 6.66 (d, 2H,
Ar-H); 6.90 (d, 2H, Ar-H); 7.28e7.38 (m, 5H, C5H5 attached
to S-CH2-); 13.80 (broad signal due to thiol-thione tauto-
meric form).
IR spectral data of 4-[3-Benzylsulfanyl-5-(4-chloro-phe-
noxymethyl)-1,2,4-triazole-4-ylmethyl]-morpholine (7a)
NH (3143 cm1); Aromatic Ar-H (3071 cm1); aliphatic
-CH2 (2936 cm
1); >C]N (1598 cm1) and N-N
(1655 cm1).
1H NMR spectral data of 4-[3-Benzylsulfanyl-5-(4-chloro-
phenoxymethyl)-1,2,4-triazole-4-ylmethyl]-morpholine (7a)
d 2.45 (m, 4H, morpholine N-CH2); 3.63 (m, 4H, mor-
pholine O-CH2-); 4.63 (s, 2H, >CH2); 5.20 (s, 2H, -S-CH2-);
5.80 (s, 2H, -O-CH2-); 6.69 (d, 2H, Ar-H); 6.94 (d, 2H, Ar-
H); 7.36e7.44 (m, 5H, C5H5 attached to S-CH2-).
Spectral data of 4-[(3-(4-Chloro-phenoxymethyl)-5-
(4-substituted-benzylsulfonyl)-1,2,4-triazol-4-yl)methyl]-
morpholine 8 (IR-nmax in cm
1, 1H NMR (300MHz, DMSO-
d6) d ppm.
IR spectral data of 8a: 1028 (CeS); 1518 (C]N);1613 (N-
N).
1H NMR spectral data of 8a: 2.48-2.52 (m, 4H, mor-
pholine N-CH2); 3.60e3.70 (m, 4H, morpholine O-CH2-);
4.68 (s, 2H, >CH2); 4.89 (s, 2H, -SO2-CH2); 5.23 (s, 2H, -O-
CH2-); 6.50 (d, 2H, Ar-H); 6.88 (d, 2H, Ar-H); 7.01e7.19 (m,
5H, C5H5 attached to S-CH2-);
IR spectral data of 8b: 1030 (CeS); 1520 (C]N); 1616
(N-N).
1H NMR spectral data of 8b: 2.30e2.60 (m, 4H, mor-
pholine N-CH2); 2.80 (s, 3H, -CH3); 3.80e3.90 (m, 4H,
morpholine O-CH2-); 4.60 (s, 2H, >CH2); 4.83 (s, 2H, -SO2-
CH2); 5.13 (s, 2H, -O-CH2-); 6.42 (d, 2H, Ar-H); 6.84 (d, 2H,
Ar-H); 7.03 (d, 2H, Ar-H); 7.13 (d, 2H, Ar-H).
IR spectral data of 8c: 1032 (CeS); 1523 (C]N); 1628
(N-N).
1H NMR spectral data of 8c: 2.52e2.56 (m, 4H, mor-
pholine N-CH2); 3.90e4.00 (m, 4H, morpholine O-CH2-);)-5-(4-substituted-benzylsulfonyl)-1,2,4-triazol-4-yl)methyl]-mor-
nd (calculated)
N O S Cl
8 (5.01) 12.45 (12.10) 13.62 (13.82) 6.97 (6.93) 7.83 (7.66)
7 (5.28) 11.92 (11.75) 13.65 (13.42) 6.85 (6.72) 7.67 (7.43)
9 (5.11) 11.67 (11.37) 16.65 (16.23) 6.78 (6.50) 7.35 (7.19)
1 (4.37) 13.70 (13.79) 19.42 (18.90) 6.58 (6.31) 7.22 (6.98)
9 (4.46) 11.55 (11.26) 13.12 (12.87) 6.23 (6.45) 14.02 (14.26)
6 (4.09) 9.79 (10.34) 12.12 (11.81) 6.34 (5.92) 6.12 (6.54)
3 (4.61) 11.21 (11.65) 13.49 (13.31) 6.98 (6.67) 7.56 (7.37)
Pharmacological studies of sulphur containing 1,2,4-triazole derivatives 2973.40 (s, 3H, -CH3); 4.69 (s, 2H, >CH2); 4.90 (s, 2H, -SO2-
CH2-); 5.25 (s, 2H, -O-CH2-); 6.53 (d, 2H, Ar-H); 6.88 (d,
2H, Ar-H); 6.90 (d, 2H, Ar-H); 7.19 (d, 2H, Ar-H).
IR spectral data of 8d: 1038 (CeS); 1530 (C]N); 1625
(N-N).
1H NMR spectral data of 8d: 2.58e2.61 (m, 4H, mor-
pholine N-CH2); 4.00e4.20 (m , 4H, morpholine O-CH2-);
4.70 (s, 2H, >CH2); 4.91 (s, 2H, -SO2-CH2-); 5.28 (s, 2H, -O-
CH2-); 6.58 (d, 2H, Ar-H); 6.86 (d, 2H, Ar-H); 7.15 (d, 2H,
Ar-H); 7.90 (d,2H, Ar-H);
IR spectral data of 8e: 1029 (CeS); 1522 (C]N); 1616
(N-N).
1H NMR spectral data of 8e: 2.60e2.64 (m, 4H, mor-
pholine N-CH2); 3.80e3.90 (m, 4H, morpholine O-CH2-);
4.71 (s, 2H, >CH2); 4.92 (s, 2H, -SO2-CH2-); 5.29 (s, 2H, -O-
CH2-); 6.60 (d, 2H, Ar-H); 6.87 (d, 2H, Ar-H); 7.10 (d, 2H,
Ar-H); 7.43 (d,2H, Ar-H);
IR spectral data of 8f: 1027 (CeS); 1524 (C]N); 1617
(N-N).
1HNMR spectral data of 8f: 2.54e58 (m, 4H, morpholine
N-CH2); 3.50e3.60 (m, 4H, morpholine O-CH2-); 4.65 (s,
2H, >CH2); 4.85 (s, 2H, -SO2-CH2-); 5.26 (s, 2H, -O-CH2-);
6.54 (d, 2H, Ar-H); 6.85 (d, 2H, Ar-H); 7.12 (d, 2H, Ar-H);
7.40 (d, 2H, Ar-H);
IR spectral data of 8g: 1028 (CeS); 1526 (C]N); 1619
(N-N).
1H NMR spectral data of 8g: 2.62e65 (m, 4H, morpho-
line N-CH2); 4.00e4.20 (m, 4H, morpholine O-CH2-); 4.71
(s, 2H,>CH2); 4.93 (s, 2H, -SO2-CH2-); 5.30 (s, 2H, -O-CH2-
); 6.62 (d, 2H, Ar-H); 6.89 (d, 2H, Ar-H); 7.12 (d, 2H, Ar-H);
6.90 (d, 2H, Ar-H):Discussion
2-(4-Chlorophenoxy)acetohydrazide (3) was obtained
by the treatment of Hydrazine hydrate with Ethyl-2-N
O
Cl
O
N N
N O
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Scheme 2: Mass spectral fragmentation details of 4-[(3-(4-Chloro-phen
8a.(4-chlorophenoxy)acetate (2) in Ethanol medium. An
aqueous solution of 3 on treatment with Potassium thio-
cyanate in presence of HCl resulted in the formation of 1-
(2-(4-Chlorophenoxy) acetyl) thiosemicarbazide (4) which
on further treatment with an aqueous solution of K2CO3
yielded 5-(4-Chlorophenoxymethyl)-2,4-dihydro-1,2,4-
triazole-3-thione (5). 5 on treatment with p-substituted
Benzyl chloride in an Ethanolic solution of KOH resulted
in the formation of corresponding triazole 6. The corre-
sponding Mannich product of 7 series was obtained by the
reaction of 6 with an aqueous solution of Morpholine
which further was converted into sulfonyl derivative (8a-
g). The formation of products at each step was confirmed
by elemental and spectral analysis. Mass spectral frag-
mentation of 4-[(3-(4-Chloro-phenoxymethyl)-5-
benzylsulfonyl-1,2,4-triazol-4-yl)methyl]-morpholine 8a is
presented in Scheme 2. The molecular ion peak was
observed at m/z 462(21.6%), the base peak was at m/z
222(100%), other prominent peaks were appeared at m/z
68(17.8%), 236(20.7%), 322(27.6%), 308(19.5%) and
363(24.1%).Antimicrobial activity
The preliminary antimicrobial activity of synthesized
compounds was investigated by disc diffusion method19
against the following pathogenic organisms. The gram
positive bacteria screened were Staphylococcus aureus
NCCS 2079 and Bacillus cereus NCCS 2106. The gram
negative bacterial screened were Escherichia coli NCCS 265
and Pseudomonas aeruginosa NCCS2200. The fungi
screened were Aspergillus niger NCCS 1196 and Candida
albicans NCCS 3471. Minimum inhibitory concentration
was found by broth dilution method.20
The results (Tables 2 and 3) showed that all the novel
compounds were active against the tested microbes.S
O
H
Cl
O
N N
N
S
O O
-C5H10NO
-C7H7SO2
N
O
Cl
O
N N
N
+
.6%)
-C12H16ClNO2
N N
N+
m/z 68 (17.8%)
6ClO
5H10NO
0%)
.6%) m/z 308 (19.5%)
m/z 363 (24.1%)
oxymethyl)-5-benzylsulfonyl-1,2,4-triazol-4-yl)methyl]-morpholine
Table 2: Antimicrobial activity of 4-[(3-(4-Chloro-phenoxymethyl)-5-(4-substituted-benzylsulfonyl)-1,2,4-triazol-4-yl)methyl]-mor-
pholine 8.
Compound (50 mg/mL) Zone inhibition (mm)a
Staphylococus
aureus
NCCS 2079
Bacillus Cereus
NCCS 2106
Escherichia coli
NCCS 2065
Pseudomanas
aeruginos
NCCS 2200
Aspergillus niger
NCCS 1196
Candida albicans
NCCS 2106
8a 7.17 4.67 7.33 4.83 5.83 7.67
8b 6.83 5.17 6.33 6.5 6.83 7.00
8c 6.00 3.33 5.67 6.00 5.83 7.33
8d 15.17 13.83 12.17 12.00 16.00 16.17
8e 14.00 12.17 10.83 11.00 14.83 14.50
8f 12.00 10.83 8.50 7.50 14.17 11.50
8g 13.17 11.33 9.17 9.00 14.83 12.33
Cefaclor (10 mg/mL) 19.83 22.00 20.00 20.17 e e
Ketoconazole (25 mg/mL) e e e e 22.17 24.83
a Average of six determinations.
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that of standards tested. Compound ‘8d’ i.e. containing
nitro group at 4 position exhibited highest antimicrobial
activity among the title compounds followed by
compounds ‘8 e, g and f’ containing halogen group at 4
position. The antimicrobial activity of compounds under
investigation is in the order d > e > g > f > a > b > c.
Octanol-water partition coefficient is expressed in terms
of milogP and is a measure of molecular hydrophobicity in
rational drug design. All the values are found to be well
within the accepted range.21 As per the computationally
predicted characteristics, their pharmacological activity is
of the order e > g > c > a > b > d > f. The compound
8e with chloro substituent is predicted to possess
excellent drug-like characteristics among the compounds
under study. In the case of compounds 8d and f, Table 4
indicates violations as a result of higher molecular weight
and higher number of donor atoms.22 However, it is
frequently necessary to work with compounds of high
molecular weight to achieve preferred drug features.
Daniel et al.23 suggests that success in achieving high oral
bioavailability depends up on molecular rigidity andTable 3: Minimum inhibitory concentration of 4-[(3-(4-Chloro-ph
methyl]-morpholine 8.
Compound Minimum inhibitory concentration (mg/mL)  SDa
Staphylococus
aureus
NCCS 2079
Bacillus Cereus
NCCS 2106
Escherichia
NCCS 2065
8a 15.24  0.08 18.18  0.07 14.41  0.0
8b 16.12  0.11 17.74  0.06 15.05  0.0
8c 19.29  0.14 21.36  0.16 18.25  0.0
8d 5.17  0.11 6.32  0.13 7.08  0.1
8e 6.08  0.16 6.85  0.12 7.10  0.1
8f 8.19  0.13 7.84  0.11 10.07  0.1
8g 6.63  0.18 7.08  0.17 8.34  0.1
Cefaclor 2.08  0.15 4.04  0.13 3.02  0.1
Ketoconazole e e e
Pharmacophore analysis.
Drug like properties mentioned in Table 4 is predicted from Molinspir
a n ¼ 6; SD ¼ Standard deviation.polar surface area without specific reference to molecular
weight. Though high molecular weight, non bonded
intramolecular interactions lead to reduced flexibility in
large cyclic molecules, it was reported that23 reported
that efficient selective criteria for oral bioavailability is a
result of precise combination of factors such as polar
surface area (PSA)  140 A, number of rotatable bonds
10 and sum of H-bond donors and acceptors 12
without specific limit to molecular weight.Conclusion
All 1,2,4-triazole derivatives reported showed good anti-
bacterial and antifungal activities. The preliminary antimi-
crobial activity studies were done by disc diffusion method
and minimum inhibitory concentration was found out by
broth dilution method. Compounds 8a, b and c showed
moderate antimicrobial activity. Compounds 8d, e, f and g
namely nitro, chloro, bromo and fluoro derivatives respec-
tively, showed better antimicrobial activity than the other
compounds. Virtual screening studies revealed that theenoxymethyl)-5-(4-substituted-benzylsulfonyl)-1,2,4-triazol-4-yl)
coli Pseudomanas
aeruginos
NCCS 2200
Aspergillus niger
NCCS 1196
Candida albicans
NCCS 2106
9 19.49  0.07 21.62  0.18 17.47  0.22
7 15.62  0.04 16.17  0.29 16.28  0.26
9 18.43  0.12 19.30  0.23 17.39  0.23
3 8.13  0.13 5.30  0.24 5.44  0.23
4 8.19  0.07 5.71  0.22 5.66  0.23
4 9.51  0.15 6.57  0.27 7.37  0.20
1 7.29  0.21 6.40  0.21 7.19  0.25
5 3.00  0.16 e e
e 0.75  0.15 0.47  0.13
ation Cheminformatics 2014 and admet SAR.
Table 4: Pharmacophore analysis of title compounds.
Pharmacophore Characteristic 8a 8b 8c 8d 8e 8f 8g
aToxicity AMES toxicity (all are classified
as non AMES toxic)
0.5706 0.5726 0.5688 0.5000 0.5702 0.5669 0.5706
Carcinogens (all are classified
as non-carcinogens)
0.6274 0.6028 0.6423 0.5823 0.6248 0.6327 0.6274
bProperties miLogP 3.145 3.594 3.202 3.104 3.309 3.954 3.823
TPSA 86.566 86.566 95.8 132.39 86.566 86.566 86.566
natoms 31 32 33 34 32 32 32
MW 462.959 476.986 492.985 507.956 480.949 541.856 497.404
nON 8 8 9 11 8 8 8
nOHNH 0 0 0 0 0 0 0
nviolations 0 0 0 2 0 1 0
nrotb 8 8 9 9 8 8 8
volume 386.406 402.967 411.952 409.74 391.338 404.292 399.942
aAqueous solubility (LogS) 3.8442 3.8442 3.7324 3.8394 3.8411 3.8422 3.8442
aCaco2 Permeability (LogPapp, cm/s) 0.6542 0.7196 0.6885 0.7388 0.6598 0.6499 0.6542
bBioactivity GPCR ligand 0.35 0.38 0.36 0.44 0.35 0.42 0.34
Ion channel modulator 0.75 0.78 0.74 0.73 0.73 0.79 0.74
Kinase inhibitor 0.31 0.33 0.3 0.39 0.3 0.34 0.28
Nuclear receptor ligand 0.62 0.62 0.61 0.64 0.6 0.69 0.58
Protease inhibitor 0.45 0.48 0.45 0.52 0.43 0.53 0.46
Enzyme inhibitor 0.32 0.36 0.33 0.38 0.31 0.37 0.33
a Predicted using admet SAR.
b Molinspiration cheminformatics 2014.
Pharmacological studies of sulphur containing 1,2,4-triazole derivatives 299compounds under study possess excellent drug-like
characteristics.
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